We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The agency will respond to 90 percent of priority major ANDA amendments within six months in cases where preapproval inspection is not required. Read More
The allegations “suggest that PBMs and drug distributors are acting to maintain high list prices in order to maintain high profit margins, potentially raising antitrust concerns,” the June 29 letters state. Read More
The U.S. Attorney for the Southern District of New York filed a lawsuit against an herbal drug manufacturer for selling unapproved drugs using claims that they can cure or prevent conditions including diabetes, syphilis, arthritis, cancer, heart disease and asthma. Read More
The FDA released final guidance Tuesday spelling out its review goals for amendments to abbreviated new drug applications and prior approval supplements under GDUFA II. Read More
Nearly nine in 10 professionals who prescribed Mallinckrodt’s HP Acthar gel (repository corticotropin) to Medicare patients in 2015 received some compensation from the company, a new study by Oregon researchers claims. Read More
The National Association of Medicaid Directors called the decision “disappointing for Massachusetts and for a lot of other states that really want to do something similar.” Read More